Alzheimer's Drug Dimebon Fails, Pitiable Day
Medivation (MDVN) too Pfizer (PFE) Announce Results from Phase 3 Concert Trial of Dimebon inward Alzheimer’s Disease
By Bob DeMarco
Medivation too Pfizer volition discontinue evolution of dimebon for all indications too volition terminate the ongoing opened upwards label extension report inward Alzheimer’s disease. The companies too denote that they volition terminate their collaboration to co-develop too marketplace dimebon pursuant to the price of their Collaboration Agreement.
Baca Juga
 |
| Dotty 95 Years Old |
As some of you lot know, Dotty was enrolled inward a Dimebon clinical case too amongst real skillful result. See Reflections on Dotty too Dimebon.
This brings the pose out of consecutive failed clinical trials for Alzheimer's medications to 15.
| Subscribe to the |
Medivation (MDVN) too Pfizer (PFE) Announce Results from Phase 3 Concert Trial of Dimebon inward Alzheimer’s Disease
Medivation, Inc. (NASDAQ: MDVN) too Pfizer Inc. (NYSE: PFE) today announced results from the CONCERT trial, which is a Phase 3 case that evaluated dimebon (latrepirdine) when added to ongoing handling amongst donepezil HCL tablets inward patients amongst mild-to-moderate Alzheimer’s disease.
Dimebon did non laissez passer on statistically important results for either of the 2 co-primary endpoints, the Alzheimer’s Disease Assessment Scale – cognitive subscale (ADAS-cog), which measures cognitive ability, or the Alzheimer’s Disease Cooperative Study – Activities of Daily Living (ADCS-ADL), which measures self tending too daily function.
“We are disappointed inward the CONCERT results too the implications for Alzheimer’s affliction patients too their caregivers,” said David Hung, M.D., president too CEO of Medivation. “I would similar to extend my sincere thank you lot to the patients, their physicians too report teams involved inward this trial.”
Dimebon was to a greater extent than oftentimes than non good tolerated inward the study. Influenza A virus subtype H5N1 total analysis of the results from CONCERT volition hold out conducted too submitted for presentation at an upcoming scientific congress.
Medivation too Pfizer volition discontinue evolution of dimebon for all indications too volition terminate the ongoing opened upwards label extension report inward Alzheimer’s disease. The companies too denote that they volition terminate their collaboration to co-develop too marketplace dimebon pursuant to the price of their Collaboration Agreement.
“We recognize Alzheimer’s is a real complex disease,” said Steven J. Romano, M.D., senior vice president, head, Medicines Development Group, Global Primary Care Business Unit, Pfizer Inc. “Despite this disappointing result, Pfizer remains committed to advancing the scientific discipline of Alzheimer’s disease, amongst the ultimate destination of delivering innovative too meaningful novel handling options to patients.”
The Phase 3 CONCERT case was a 12-month global randomized, double-blind, placebo-controlled case that enrolled 1,003 patients amongst Alzheimer’s disease. Patients on a stable dose of donepezil for at to the lowest degree iv months were randomized to i of 3 handling groups: dimebon twenty mg 3 times per day, dimebon five mg 3 times per 24-hour interval or placebo.
About Medivation
Medivation, Inc. is a biopharmaceutical companionship focused on the rapid evolution of novel small-scale molecule drugs to process serious diseases for which at that spot are express handling options. Medivation aims to transform the handling of these diseases too offering promise to critically sick patients too their caregivers. Together amongst its corporate partner Astellas, Medivation currently has its investigational drug MDV3100 inward Phase 3 evolution to process advanced prostate cancer. For to a greater extent than information, delight catch us at www.medivation.com.
Pfizer Inc.: Working together for a healthier world™
At Pfizer, nosotros apply scientific discipline too our global resources to ameliorate wellness too well-being at every phase of life. We strive to ready the criterion for quality, security too value inward the discovery, evolution too manufacturing of medicines for people too animals. Our diversified global wellness tending portfolio includes human too animate beingness biologic too small-scale molecule medicines too vaccines, every bit good every bit nutritional products too many of the world's best-known consumer products. Every day, Pfizer colleagues piece of job across developed too emerging markets to advance wellness, prevention, treatments too cures that challenge the most feared diseases of our time. Consistent amongst our responsibleness every bit the world's leading biopharmaceutical company, nosotros too collaborate amongst wellness tending providers, governments too local communities to back upwards too expand access to reliable, affordable wellness tending merely about the world. For to a greater extent than than 150 years, Pfizer has worked to brand a deviation for all who rely on us. To larn to a greater extent than virtually our commitments, delight catch us at Pfizer.com.
Related content.
- What’s the Difference Between Alzheimer’s Disease too Dementia
- Test Your Memory for Alzheimer's (5 Best Self Assessment Tests)
- How Alzheimer's Spreads Throughout the Brain
- What is Dementia?
- Communicating inward Alzheimer's World
- How the Loss of Memory Works inward Alzheimer’s Disease, too How Understanding This Could Help You
- Learning How to Communicate amongst Someone Suffering From Alzheimer's Disease
- Does the Combination of Aricept too Namenda Help Slow the Rate of Decline inward Alzheimer's Patients
Original content Bob DeMarco, the
